Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2018 07:10 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

SALT LAKE CITY, April 27, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president...
April 27, 2018 07:05 ET | Source: Myriad Genetics, Inc.

New Study Finds that 24 Percent of Women Seen in the Obstetrics-Gynecology Setting Met NCCN Guidelines for Hereditary Cancer Genetic Testing

SALT LAKE CITY, April 27, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that results from a large...
April 19, 2018 09:05 ET | Source: Myriad Genetics, Inc.

Myriad Announces Launch of "Go Green" Sustainability Initiative In Support of Earth Day

SALT LAKE CITY, April 19, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced the launch of its new Go Green sustainability...
April 17, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Myriad to Announce Fiscal Third-Quarter 2018 Financial Results on May 8, 2018

SALT LAKE CITY, April 17, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will hold its fiscal...
April 02, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Receives Pre-Market Approval for its BRACAnalysis® Diagnostic System in Japan

SALT LAKE CITY, April 02, 2018 (GLOBE NEWSWIRE) -- Myriad Genetic Laboratories, Inc., a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), announced today that the Japanese Ministry of...
March 06, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Applauds AACU Position Statement on Molecular Testing for Risk Stratification in Prostate Cancer

SALT LAKE CITY, March 06, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, announced today that the American Association of Clinical...
March 01, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Demonstrates Strong Commitment to Preventing Hereditary Colon Cancer as Part of National Colorectal Cancer Awareness Month

SALT LAKE CITY, March 01, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, continues to demonstrate an unmatched commitment...
February 27, 2018 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

SALT LAKE CITY, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president...
February 20, 2018 07:05 ET | Source: Myriad Genetics, Inc.

NCCN Guidelines Broadly Endorse Biomarker Testing in Prostate Cancer

SALT LAKE CITY, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that the National Comprehensive Cancer Network (NCCN) has updated its medical guidelines for...
February 15, 2018 11:15 ET | Source: Myriad Genetics, Inc.

JAMA Oncology Publication Demonstrates EndoPredict® (EPClin) Significantly Outperforms Oncotype DX® Recurrence Score in Early-Stage Breast Cancer

SALT LAKE CITY, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients...